Eli Lilly invests $3.5B in Pennsylvania plant, plans 2,850 jobs
The FDA PreCheck pilot begins accepting applications for U.S. pharmaceutical plants, with initial selections expected in 2026 to accelerate domestic drug manufacturing. Eli Lilly is investing $3.5B in a Pennsylvania injectable-medicine facility for weight-loss therapies like retatrutide, creating 850 permanent and 2,000 construction jobs with operations starting in 2031.
1. Q4 2025 Earnings and Revenue Performance
Eli Lilly reported fourth-quarter revenue of $19.3 billion, a 43% increase from $13.5 billion a year earlier, driven by a 46% increase in volume that was partially offset by a 5% decline in realized prices. Reported EPS rose 51% to $7.39, while non-GAAP EPS increased 42% to $7.54, both figures inclusive of $0.52 per share in acquired IPR&D charges. Key Products revenue reached $13.8 billion, led by Mounjaro sales of $7.4 billion (up 110%) and Zepbound sales of $4.3 billion (up 123%). U.S. revenue jumped 43% to $12.9 billion, and international revenue also increased 43% to $6.4 billion, reflecting strong global demand for the company’s diabetes and obesity treatments.
2. 2026 Financial Guidance and Pipeline Progress
For fiscal 2026, Eli Lilly issued revenue guidance of $80.0 billion to $83.0 billion and non-GAAP EPS guidance of $33.50 to $35.00, both levels exceeding consensus estimates. On the regulatory front, the company secured FDA approval of Kwikpen for tirzepatide and expanded the indication for Jaypirca (pirtobrutinib), while submitting orforglipron dossiers for obesity in the U.S., EU and Japan. Notable clinical milestones include positive Phase 3 data for Taltz plus Zepbound in psoriatic arthritis patients with obesity, successful oral GLP-1 results for orforglipron, and Phase 3 efficacy of retatrutide in obesity with knee osteoarthritis. In addition, Eli Lilly finalized an agreement with the U.S. government to broaden access to its obesity medicines.
3. U.S. Manufacturing Expansion
In response to the FDA’s new PreCheck pilot program for domestic drug manufacturing, Eli Lilly announced a $3.5 billion investment in a Pennsylvania facility dedicated to next-generation injectable weight-loss therapies, including retatrutide. Scheduled to begin construction in 2026 and become operational in 2031, this site will create 850 permanent positions and approximately 2,000 construction jobs. It marks the company’s fourth new U.S. manufacturing site since February 2025 and underscores Lilly’s commitment to strengthening the domestic pharmaceutical supply chain and meeting surging demand for its blockbuster treatments.